NMN (Nicotinamide Mononucleotide)

NMN (Nicotinamide Mononucleotide) has attracted substantial research interest as a precursor to NAD+, a molecule central to cellular energy metabolism and repair that declines with age. The available human evidence includes multiple RCTs and two meta-analyses — a comparatively robust foundation for a dietary supplement. Oral NMN supplementation has been shown to reliably raise blood NAD+ levels in adults, which is the intended proximal effect. Beyond that biomarker, human trials have reported signals in several outcome areas: one RCT found improvements in muscle insulin sensitivity in prediabetic women; another found that NMN maintained walking speed and improved sleep quality in older adults; and a separate RCT in amateur runners reported enhanced aerobic capacity. A meta-analysis specifically examined effects on skeletal muscle mass and function, and another assessed glucose and lipid metabolism outcomes across RCTs. The mechanistic pathway — NMN conversion to NAD+ via the enzyme NMNAT — is biochemically well-established. Despite these signals, important limitations temper enthusiasm. Most RCTs are short in duration (weeks to a few months), involve small participant numbers, and focus on specific populations such as postmenopausal women, older adults, or trained athletes, limiting how broadly findings can be generalized. Effect sizes for functional outcomes like physical performance and metabolic markers have been modest, and it remains unclear whether raising blood NAD+ levels translates to meaningful, sustained clinical benefits in healthy people. The meta-analyses provide the highest-quality synthesis available, but they are constrained by the same limitations as the underlying trials. Critically, no long-term human outcomes data exist — no trials spanning years or decades that track hard endpoints like cardiovascular events, cognitive decline, or longevity. Much of the mechanistic rationale for NMN still rests on animal studies, where results have been more dramatic but often do not translate directly to humans. Optimal dosing, the best-responding populations, and long-term safety beyond short trial windows remain open questions. Expert advocacy for NMN, while informed by mechanistic reasoning and early human data, currently goes meaningfully beyond what the clinical trial evidence alone can firmly support.